A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.
Saved in:
| Title: | A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors. |
|---|---|
| Authors: | Eng C; Division of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. cathy.eng@vumc.org., Lakhani NJ; The START Center for Cancer Research, Grand Rapids, MI, USA., Philip PA; Division of Hematology-Oncology, Department of Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Schneider C; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Johnson B; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kardosh A; Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Division of Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR, USA., Chao MP; Forty Seven, Inc, Menlo Park, CA, USA., Patnaik A; The START Center for Cancer Research, San Antonio, TX, USA., Shihadeh F; Gilead Sciences, Inc, Foster City, CA, USA., Lee Y; Gilead Sciences, Inc, Foster City, CA, USA., Song K; Gilead Sciences, Inc, Foster City, CA, USA., Jin D; Gilead Sciences, Inc, Foster City, CA, USA., Huo Y; Gilead Sciences, Inc, Foster City, CA, USA., Howland M; Gilead Sciences, Inc, Foster City, CA, USA., Fisher GA; Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Hecht JR; Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. |
| Source: | Targeted oncology [Target Oncol] 2025 May; Vol. 20 (3), pp. 519-530. Date of Electronic Publication: 2025 Mar 26. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1776-260X |
|---|---|
| DOI: | 10.1007/s11523-025-01130-y |
